Century Therapeutics, Inc. (IPSC)
NasdaqCM · USD · Healthcare · Biotechnology
$1.42 (-2.74%) as of
Key statistics
- Market cap
- 257.13M
- Forward P/E
- -3.16
- EPS (TTM)
- -0.9300
- Dividend yield
- 0.00%
- 52-week range
- 0.4350 – 3.0400
- Beta
- 1.67
- Profit margin
- 0.00%
- Analyst target
- $4.75
- Volume
- 493.65k
About Century Therapeutics, Inc.
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Philadelphia, PA, United States
- Employees
- 78
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.